5 Must-Read Analyst Questions From Cardinal Health's Q1 Earnings Call

Cardinal Health’s first quarter results were received positively by the market, with management attributing performance to strong execution in its Pharmaceutical and Specialty Solutions business and profit growth across all five operating segments. CEO Jason Hollar highlighted that the onboarding of new large customers and the integration of recent acquisitions, such as GI Alliance and Integrated Oncology Network, contributed to both top-line and segment profit gains. CFO Aaron Alt noted that operating leverage was achieved through a combination of disciplined cost control and efficiency initiatives, especially in the face of a flat revenue environment.

Is now the time to buy CAH? Find out in our full research report (it’s free).

While we enjoy listening to the management's commentary, our favorite part of earnings calls are the analyst questions. Those are unscripted and can often highlight topics that management teams would rather avoid or topics where the answer is complicated. Here is what has caught our attention.

Our Top 5 Analyst Questions Cardinal Health’s Q1 Earnings Call

• Lisa Gill (JPMorgan) asked about the sustainability of strong specialty and branded drug growth. CEO Jason Hollar responded that growth was broad-based and supported by secular demand, with new customer wins and GLP-1 sales contributing to volume gains.

• Allen Lutz (Bank of America) inquired about potential demand headwinds from tariffs and macroeconomic weakness. Hollar replied that pharmaceutical demand has historically been resilient during economic downturns, and no material pullback was observed.

• Eric Percher (Nephron) questioned how Cardinal Health plans to offset remaining tariff exposure. Hollar explained that most mitigation would come through operational actions and targeted price increases, particularly for Cardinal Health-branded products.

• Michael Cherny (Leerink Partners) probed the relative impact of tariffs versus other GMPD business factors. Hollar clarified that tariffs represent the main headwind, but operational improvements and cost reductions should partially offset the impact.

• Erin Wright (Morgan Stanley) requested updates on new customer onboarding and its impact on pharma growth. Hollar confirmed that $10 billion in new customer revenue was successfully onboarded and is expected to benefit results in coming quarters.

Catalysts in Upcoming Quarters

In the coming quarters, the StockStory team will be monitoring (1) the pace and profitability of new customer and acquisition integrations, (2) sustained demand and margin trends in specialty pharmaceuticals, and (3) Cardinal Health’s ability to mitigate tariff-related cost pressures in GMPD. Progress in ancillary businesses and the ramp-up of automation and technology investments will also be key markers of execution.

Cardinal Health currently trades at $163.76, up from $141.14 just before the earnings. In the wake of this quarter, is it a buy or sell? The answer lies in our full research report (it’s free).

The Best Stocks for High-Quality Investors

The market surged in 2024 and reached record highs after Donald Trump’s presidential victory in November, but questions about new economic policies are adding much uncertainty for 2025.

While the crowd speculates what might happen next, we’re homing in on the companies that can succeed regardless of the political or macroeconomic environment. Put yourself in the driver’s seat and build a durable portfolio by checking out our Top 9 Market-Beating Stocks. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025).

Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-micro-cap company Kadant (+351% five-year return). Find your next big winner with StockStory today.